Developer docs
API playgroundTry for free, no card

Search company profiles

Newron Pharmaceuticals

Full company profile

uuid0004lyx

Namestring
Newron Pharmaceuticals
Legal namestring
Newron Pharmaceuticals S.p.A.
Websiteurl
newron.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company founded in 1999 and headquartered in Bresso, near Milan, Italy, with a US subsidiary in Morristown, New Jersey. The company focuses on developing novel therapies for diseases of the central and peripheral nervous system (CNS), operating a concentrated team of approximately 30 scientists, researchers, and clinicians with more than 25 years of proprietary research heritage. Newron is publicly listed on the SIX Swiss Exchange (ticker: NWRN) and additionally on the primary market of the Düsseldorf Stock Exchange and XETRA (trading symbol NP5).

The company's pipeline is anchored by evenamide, a first-in-class oral glutamate modulator being evaluated as an add-on therapy for treatment-resistant schizophrenia (TRS). Evenamide selectively inhibits voltage-gated sodium channels in hyper-active neurons to normalize glutamatergic dysfunction without interfering with over 150 CNS receptors, enzymes, or transporters. It is being assessed in two global pivotal Phase III trials — ENIGMA-TRS 1 (52-week, 600+ patients, initiated August 2025) and ENIGMA-TRS 2 (12-week, 400+ patients, initiated December 2025) — with pivotal results expected in Q4 2026 and a regulatory approval target of 2027. Newron's commercial asset is Xadago (safinamide), a once-daily selective MAO-B inhibitor approved for Parkinson's disease. Earlier-stage pipeline includes ralfinamide, a sodium/calcium/NMDA channel modulator for rare neuropathic pain, for which Newron is seeking a development partner. The company holds a registered patent on crystalline forms of evenamide.

Newron operates primarily through a licensing and partnership business model rather than direct sales. Revenue is generated via upfront payments, milestones, and royalties from regional commercialization partners, including EA Pharma (an Eisai subsidiary) for evenamide in Japan and other Asian territories — which generated a $46.1 million upfront in late 2024 — and Myung In Pharm for South Korea. The company supplements partner capital with equity raises, most recently a February 2026 share subscription of up to EUR 38 million structured in tranches tied to Phase III progress, and debt financing from the European Investment Bank, whose 2018 loan repayment dates were extended to June 2028.

Short descriptiontext

Newron Pharmaceuticals is a biopharmaceutical company developing novel CNS therapies, including evenamide (Phase III for treatment-resistant schizophrenia) and the approved Parkinson's drug Xadago/safinamide, monetizing its pipeline through regional licensing partnerships in Europe, Asia, and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBresso, Italy
HQ citystring
Bresso
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug development, central nervous system therapeutics, treatment-resistant schizophrenia, Parkinson's disease therapy, neuropathic pain treatment
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Central Nervous System (CNS) Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Commercialization Agreements
TypeLicensing Royalties
Description

Newron generates revenue through licensing deals for its drug candidates. Received $46.1 million upfront payment from EA Pharma for evenamide rights in Japan and Asian territories, with potential additional milestone payments.

newron.com
2Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue pharmaceutical company focused on developing novel CNS therapies from discovery through commercialization.

newron.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Xadago (safinamide)
Description

A New Chemical Entity for the treatment of Parkinson's Disease with a mode of action characterized by selective MAO-B-inhibition.

newron.com
+2 more records
Core offering1 text field

Newron Pharmaceuticals is a biopharmaceutical company that develops proprietary new chemical entities for diseases of the central and peripheral nervous system, with its lead asset evenamide in pivotal Phase III for treatment-resistant schizophrenia, Xadago (safinamide) approved for Parkinson's disease, and ralfinamide in development for rare neuropathic pain. The company monetizes these assets primarily through regional licensing and commercialization partnerships with established pharmaceutical companies rather than through its own sales force.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central and peripheral nervous system. The company operates as a single-product portfolio company with multiple drug candidates in its pipeline. Its core products include Evenamide (Phase III, novel glutamate modulator for treatment-resistant schizophrenia), Xadago (safinamide, an approved MAO-B inhibitor for Parkinson's Disease), and Ralfinamide (preclinical/early development for neuropathic pain). The pipeline includes ENIGMA-TRS 1 (52-week study, 600+ patients, initiated August 2025) and ENIGMA-TRS 2 (12-week study, 400+ patients, initiated December 2025) as pivotal Phase III studies for evenamide. The company has development and commercialization agreements with EA Pharma for Japan and Asian territories, and with Myung In Pharm for South Korea.

Product and service3 records
1Evenamide
CategoryCentral nervous system therapeutics - treatment-resistant schizophrenia
Description

Evenamide is a novel oral new chemical entity and first-in-class glutamate modulator being developed by Newron as an add-on therapy to existing antipsychotics for treatment-resistant schizophrenia (TRS) and chronic schizophrenia with poor response to standard treatment. It selectively inhibits voltage-gated sodium channels in hyper-active neurons, normalizing hippocampal and cortical glutamatergic dysfunction without interfering with over 150 receptors, enzymes, or transporters involved in CNS activity. In Phase II studies, over 70% of TRS patients showed reduced disease severity, 25% achieved remission, and nearly 50% were no longer considered to have TRS after one year of treatment, with no patient relapsing.

2Xadago (safinamide)
CategoryCentral nervous system therapeutics - Parkinson's disease
Description

Xadago (safinamide) is a New Chemical Entity developed by Newron for the treatment of Parkinson's Disease, with a mode of action characterized by selective MAO-B inhibition. It provides statistically significant increases in ON-time without troublesome dyskinesia, decreases OFF-time, requires once-daily dosing, and has no diet restrictions due to its high MAO-B versus MAO-A selectivity. Commercialized globally through Newron's regional licensing partners.

3Ralfinamide
CategoryCentral nervous system therapeutics - rare neuropathic pain
Description

Ralfinamide is a unique, well-tolerated New Chemical Entity originating from Newron's ion channel program, specifically targeting voltage-gated sodium channels (Nav 1.7), N-type Calcium channels, and the NMDA receptor. It is being developed for a rare neuropathic pain indication, and Newron is seeking partners to advance the program into potentially pivotal studies in orphan indications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS-focused biopharma whose lead product Caplyta (lumateperone) is approved for schizophrenia and adjunctive treatment of major depressive disorder. Most directly comparable to Newron as a small/mid-cap CNS innovator competing in the same psychiatry prescriber audience.

TypeDirect peer
Description

Developed xanomeline-trospium (Cobenfy), the first muscarinic agonist approved for schizophrenia — a novel-mechanism antipsychotic competing for the same TRS-adjacent prescriber base and demonstrating the commercial appetite for mechanistically differentiated schizophrenia therapies.

TypeBroad incumbent
Description

Established CNS specialist with Nuplazid (pimavanserin) approved for Parkinson's disease psychosis; comparable commercial footprint in Parkinson's-adjacent indications and similar small-cap CNS commercialization dynamics.

TypeBroad incumbent
Description

CNS-focused specialty pharma with approved schizophrenia and depression products (ARISTADA, LYBALVI). Operates at larger scale but shares Newron's strategic positioning around CNS innovation and licensing-driven growth.

TypeDirect peer
Description

Mid-cap CNS innovator with Auvelity (dextromethorphan/bupropion) approved for MDD and other CNS pipeline assets; comparable business model of developing novel-mechanism CNS therapies and competing for the same neurology/psychiatry specialty audience.

TypeBroad incumbent
Description

Specialty pharma focused on CNS disorders including Parkinson's disease (Apokyn, Onapgo) and epilepsy; comparable strategic emphasis on differentiated CNS therapies with similar commercial-stage dynamics.

TypeDirect peer
Description

CNS-focused innovator developing novel mechanisms for depression and neurology; was acquired by Biogen. Representative of the strategic-exit pathway available to late-stage CNS biotechs and a relevant comparable on pipeline economics and partnership dynamics.

TypeBroad incumbent
Description

Global CNS-focused pharmaceutical company with deep schizophrenia franchise (Rexulti) and Parkinson's assets; serves as both a competitive incumbent and a potential strategic-partner archetype for late-stage CNS assets like evenamide.

TypeBroad incumbent
Description

Major CNS player with Abilify/Abilify Maintena (aripiprazole) franchise in schizophrenia; relevant comparable for evenamide's commercial and competitive positioning and a likely strategic-partner candidate for ex-Asia rights.

TypeEmerging player
Description

Smaller CNS-focused biopharma with approved acute agitation therapies (IGALMI) and an early commercial CNS footprint; comparable in scale and strategic posture to Newron as it transitions from clinical to early commercial CNS stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Newron Pharmaceuticals

Central Nervous System (CNS) Biopharmaceuticalsnewron.com

Newron Pharmaceuticals is a biopharmaceutical company developing novel CNS therapies, including evenamide (Phase III for treatment-resistant schizophrenia) and the approved Parkinson's drug Xadago/safinamide, monetizing its pipeline through regional licensing partnerships in Europe, Asia, and the US.

What Newron Pharmaceuticals does

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company founded in 1999 and headquartered in Bresso, near Milan, Italy, with a US subsidiary in Morristown, New Jersey. The company focuses on developing novel therapies for diseases of the central and peripheral nervous system (CNS), operating a concentrated team of approximately 30 scientists, researchers, and clinicians with more than 25 years of proprietary research heritage. Newron is publicly listed on the SIX Swiss Exchange (ticker: NWRN) and additionally on the primary market of the Düsseldorf Stock Exchange and XETRA (trading symbol NP5).

The company's pipeline is anchored by evenamide, a first-in-class oral glutamate modulator being evaluated as an add-on therapy for treatment-resistant schizophrenia (TRS). Evenamide selectively inhibits voltage-gated sodium channels in hyper-active neurons to normalize glutamatergic dysfunction without interfering with over 150 CNS receptors, enzymes, or transporters. It is being assessed in two global pivotal Phase III trials — ENIGMA-TRS 1 (52-week, 600+ patients, initiated August 2025) and ENIGMA-TRS 2 (12-week, 400+ patients, initiated December 2025) — with pivotal results expected in Q4 2026 and a regulatory approval target of 2027. Newron's commercial asset is Xadago (safinamide), a once-daily selective MAO-B inhibitor approved for Parkinson's disease. Earlier-stage pipeline includes ralfinamide, a sodium/calcium/NMDA channel modulator for rare neuropathic pain, for which Newron is seeking a development partner. The company holds a registered patent on crystalline forms of evenamide.

Newron operates primarily through a licensing and partnership business model rather than direct sales. Revenue is generated via upfront payments, milestones, and royalties from regional commercialization partners, including EA Pharma (an Eisai subsidiary) for evenamide in Japan and other Asian territories — which generated a $46.1 million upfront in late 2024 — and Myung In Pharm for South Korea. The company supplements partner capital with equity raises, most recently a February 2026 share subscription of up to EUR 38 million structured in tranches tied to Phase III progress, and debt financing from the European Investment Bank, whose 2018 loan repayment dates were extended to June 2028.

Newron Pharmaceuticals firmographics

Firmographics
Name
Newron Pharmaceuticals
Legal name
Newron Pharmaceuticals S.p.A.
Website
https://newron.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Newron Pharmaceuticals is a biopharmaceutical company developing novel CNS therapies, including evenamide (Phase III for treatment-resistant schizophrenia) and the approved Parkinson's drug Xadago/safinamide, monetizing its pipeline through regional licensing partnerships in Europe, Asia, and the US.
Ownership category
akta.pro rank

Newron Pharmaceuticals industry classification

Industry
Product category
Central Nervous System (CNS) Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • CNS drug development
  • Central nervous system therapeutics
  • Treatment-resistant schizophrenia
  • Parkinson's disease therapy
  • Neuropathic pain treatment

Where Newron Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Bresso
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

Newron Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Commercialization Agreements: Newron generates revenue through licensing deals for its drug candidates. Received $46.1 million upfront payment from EA Pharma for evenamide rights in Japan and Asian territories, with potential additional milestone payments.
  2. Drug Development and Commercialization: Pre-revenue pharmaceutical company focused on developing novel CNS therapies from discovery through commercialization.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Newron Pharmaceuticals product offering

Product offering

Core offering

Newron Pharmaceuticals is a biopharmaceutical company that develops proprietary new chemical entities for diseases of the central and peripheral nervous system, with its lead asset evenamide in pivotal Phase III for treatment-resistant schizophrenia, Xadago (safinamide) approved for Parkinson's disease, and ralfinamide in development for rare neuropathic pain. The company monetizes these assets primarily through regional licensing and commercialization partnerships with established pharmaceutical companies rather than through its own sales force.

Product overview

Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central and peripheral nervous system. The company operates as a single-product portfolio company with multiple drug candidates in its pipeline. Its core products include Evenamide (Phase III, novel glutamate modulator for treatment-resistant schizophrenia), Xadago (safinamide, an approved MAO-B inhibitor for Parkinson's Disease), and Ralfinamide (preclinical/early development for neuropathic pain). The pipeline includes ENIGMA-TRS 1 (52-week study, 600+ patients, initiated August 2025) and ENIGMA-TRS 2 (12-week study, 400+ patients, initiated December 2025) as pivotal Phase III studies for evenamide. The company has development and commercialization agreements with EA Pharma for Japan and Asian territories, and with Myung In Pharm for South Korea.

Differentiator

Problem solved

Functional benefit

Brands

  • Xadago (safinamide): A New Chemical Entity for the treatment of Parkinson's Disease with a mode of action characterized by selective MAO-B-inhibition.
  • Evenamide
  • Ralfinamide

Products and services

  • Evenamide Evenamide is a novel oral new chemical entity and first-in-class glutamate modulator being developed by Newron as an add-on therapy to existing antipsychotics for treatment-resistant schizophrenia (TRS) and chronic schizophrenia with poor response to standard treatment. It selectively inhibits voltage-gated sodium channels in hyper-active neurons, normalizing hippocampal and cortical glutamatergic dysfunction without interfering with over 150 receptors, enzymes, or transporters involved in CNS activity. In Phase II studies, over 70% of TRS patients showed reduced disease severity, 25% achieved remission, and nearly 50% were no longer considered to have TRS after one year of treatment, with no patient relapsing.
  • Xadago (safinamide) Xadago (safinamide) is a New Chemical Entity developed by Newron for the treatment of Parkinson's Disease, with a mode of action characterized by selective MAO-B inhibition. It provides statistically significant increases in ON-time without troublesome dyskinesia, decreases OFF-time, requires once-daily dosing, and has no diet restrictions due to its high MAO-B versus MAO-A selectivity. Commercialized globally through Newron's regional licensing partners.
  • Ralfinamide Ralfinamide is a unique, well-tolerated New Chemical Entity originating from Newron's ion channel program, specifically targeting voltage-gated sodium channels (Nav 1.7), N-type Calcium channels, and the NMDA receptor. It is being developed for a rare neuropathic pain indication, and Newron is seeking partners to advance the program into potentially pivotal studies in orphan indications.

Companies that use Newron Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

Newron Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Newron Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Newron Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Intra-Cellular Therapies: CNS-focused biopharma whose lead product Caplyta (lumateperone) is approved for schizophrenia and adjunctive treatment of major depressive disorder. Most directly comparable to Newron as a small/mid-cap CNS innovator competing in the same psychiatry prescriber audience.
  • Karuna Therapeutics: Developed xanomeline-trospium (Cobenfy), the first muscarinic agonist approved for schizophrenia — a novel-mechanism antipsychotic competing for the same TRS-adjacent prescriber base and demonstrating the commercial appetite for mechanistically differentiated schizophrenia therapies.
  • Axsome Therapeutics: Mid-cap CNS innovator with Auvelity (dextromethorphan/bupropion) approved for MDD and other CNS pipeline assets; comparable business model of developing novel-mechanism CNS therapies and competing for the same neurology/psychiatry specialty audience.
  • Sage Therapeutics: CNS-focused innovator developing novel mechanisms for depression and neurology; was acquired by Biogen. Representative of the strategic-exit pathway available to late-stage CNS biotechs and a relevant comparable on pipeline economics and partnership dynamics.

Broad incumbents

  • ACADIA Pharmaceuticals: Established CNS specialist with Nuplazid (pimavanserin) approved for Parkinson's disease psychosis; comparable commercial footprint in Parkinson's-adjacent indications and similar small-cap CNS commercialization dynamics.
  • Alkermes: CNS-focused specialty pharma with approved schizophrenia and depression products (ARISTADA, LYBALVI). Operates at larger scale but shares Newron's strategic positioning around CNS innovation and licensing-driven growth.
  • Supernus Pharmaceuticals: Specialty pharma focused on CNS disorders including Parkinson's disease (Apokyn, Onapgo) and epilepsy; comparable strategic emphasis on differentiated CNS therapies with similar commercial-stage dynamics.
  • Lundbeck: Global CNS-focused pharmaceutical company with deep schizophrenia franchise (Rexulti) and Parkinson's assets; serves as both a competitive incumbent and a potential strategic-partner archetype for late-stage CNS assets like evenamide.
  • Otsuka Pharmaceutical: Major CNS player with Abilify/Abilify Maintena (aripiprazole) franchise in schizophrenia; relevant comparable for evenamide's commercial and competitive positioning and a likely strategic-partner candidate for ex-Asia rights.

Emerging players

  • BioXcel Therapeutics: Smaller CNS-focused biopharma with approved acute agitation therapies (IGALMI) and an early commercial CNS footprint; comparable in scale and strategic posture to Newron as it transitions from clinical to early commercial CNS stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Newron Pharmaceuticals social profiles

Digital presence

Newron Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Newron Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Newron Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Newron Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Newron Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newron Pharmaceuticals

What does Newron Pharmaceuticals do?

Newron Pharmaceuticals is a biopharmaceutical company that develops proprietary new chemical entities for diseases of the central and peripheral nervous system, with its lead asset evenamide in pivotal Phase III for treatment-resistant schizophrenia, Xadago (safinamide) approved for Parkinson's disease, and ralfinamide in development for rare neuropathic pain. The company monetizes these assets primarily through regional licensing and commercialization partnerships with established pharmaceutical companies rather than through its own sales force.

Is Newron Pharmaceuticals a public or private company?

Newron Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Newron Pharmaceuticals founded?

Newron Pharmaceuticals was founded in 1999. It employs 11 to 50 people.

Where is Newron Pharmaceuticals based?

Newron Pharmaceuticals is headquartered in Bresso, Italy, in the Europe region.

How does Newron Pharmaceuticals make money?

Two revenue lines are on record. Licensing and Commercialization Agreements are the primary driver. The others are drug Development and Commercialization.

Who are Newron Pharmaceuticals's main competitors?

Direct peers on record are Intra-Cellular Therapies, Karuna Therapeutics, Axsome Therapeutics and Sage Therapeutics. Broad incumbents are ACADIA Pharmaceuticals, Alkermes, Supernus Pharmaceuticals, Lundbeck and Otsuka Pharmaceutical. BioXcel Therapeutics is listed as an emerging player.

Does Newron Pharmaceuticals have an API?

No public API is recorded for Newron Pharmaceuticals.

What industry is Newron Pharmaceuticals in?

Newron Pharmaceuticals's product category is Central Nervous System (CNS) Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comNewron Pharmaceuticals at Jefferies: evenamide drives bold schizophrenia pushNewron Pharmaceuticals presented its schizophrenia drug evenamide at the Jefferies conference, citing Phase II data with a 25% remission rate and Phase III enrollment of 1,000 patients. The Eisai partnership has delivered EUR 58.5 million, with key readouts expected in 2025. The company plans to proceed with ex-U.S. data if an FDA agreement is not reached.Business & FinancialNewron Pharmaceuticals To Participate In November Investor ConferencesNewron Pharmaceuticals will participate in the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London in November 2026. The company will present its lead compound evenamide and its marketed product Xadago, with one-on-one investor meetings available.GlobeNewswireNewron Pharmaceuticals to Participate in November Investor ConferencesNewron Pharmaceuticals will participate in the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London in November 2026. The company will present its lead compound evenamide and its marketed product Xadago, with one-on-one meetings available.FinanzNachrichten.deEin Wirkstoff, drei Kontinente: Wie Newron Substanzen weltweit auslizenziert - und warum Emyria dasselbe Prinzip auf die Therapie anwendetNewron Pharmaceuticals licenses its drugs regionally across Europe, the US, and Asia, while Emyria plans to export its psychedelic therapy protocols and training to international partners. Emyria is testing psilocybin for adjustment disorders after terminal cancer with Science Group, with potential future indications including addiction and anxiety.Seeking AlphaNewron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia TranscriptNewron Pharmaceuticals discussed the FDA's clinical hold on its ENIGMA-TRS Phase III study for treatment-resistant schizophrenia, with CEO Stefan Weber and CMO Ravi Anand reviewing the agency's feedback. The company highlighted its sodium channel pharmacology experience, including its approved product Xadago, and emphasized evenamide's novel mechanism for patients with limited therapeutic options.BioSpaceNewron reveals 5 deaths in late-stage schizophrenia program as FDA maintains holdNewron Pharmaceuticals reported four deaths among patients receiving its schizophrenia drug evenamide, with one placebo death. The FDA maintains a hold on the Phase 3 ENIGMA-TRS 2 trial, and the company is reviewing safety data. It plans to add cardiac screening and monitoring.ReutersUS FDA cites 4 deaths in Newron's schizophrenia drug trial holdThe US FDA cited four deaths and irregular heart rhythms as safety concerns behind a clinical hold on Newron Pharmaceuticals' schizophrenia drug trial at US sites. The company said trial investigators considered three deaths unrelated to the drug, and it is assessing additional heart screening. The hold remains in place, with enrollment continuing outside the US.The Pharma LetterNewron details FDA safety concerns behind evenamide hold, says Phase III continuesNewron Pharmaceuticals disclosed the FDA's reasons for a clinical hold on its evenamide Phase III ENIGMA-TRS 2 trial in treatment-resistant schizophrenia. The FDA cited sodium channel blocker risks of arrhythmias, which can cause serious cardiovascular events or seizures. Newron said it is preparing a response to the FDA's written communication.YahooUS FDA cites 4 deaths in Newron's schizophrenia drug trial holdThe US FDA cited four deaths and irregular heart rhythms as safety concerns behind a clinical hold on Newron Pharmaceuticals' schizophrenia drug trial at US sites. The deaths occurred among patients receiving evenamide, with one placebo death, and the company is assessing additional heart screening. The hold remains in place while enrollment continues outside the US.FinanzNachrichten.deNewron Pharmaceuticals Aktie: Experte senkt ErwartungenBaader Europe lowered its estimates for Newron Pharmaceuticals because FDA delays in US studies require the company to recruit and qualify additional non-US centers. The delays have left clearer marks on Baader's forecasts.